However, the 5-year survival rate of NSCLC patients is only approximately 24% since most patients eventually develop acquired resistance to first-generation EGFR-TKIs after 12–24 months of treatment [4], and EGFR wild-type patients do not benefit from targeted therapies, in contrast to EGFR mutant patients, while KRAS-mutant patients are still in lack of target therapies [5]. Here, EGFR is linked to non-small cell lung carcinoma.